Immunovia successfully completes discovery phase of next-generation test development
LUND (SWEDEN) – Immunovia (Nasdaq Stockholm: IMMNOV), the diagnostics company focused on early detection of pancreatic cancer, today announced the successful completion of the discovery phase for the Company’s next-generation test. The discovery study, which marks a key milestone in the development of Immunovia’s next-generation test to detect early-stage pancreatic cancer, successfully found more than a dozen proteins circulating in the blood that identified pancreatic ductal adenocarcinoma (PDAC) stage I and stage II patients. The study is the most comprehensive pancreatic